Epic Pharma

Executive Summary

Epic Pharma, a privately-held US generic pharmaceutical company founded in 2008, operates a 110,000 sq ft cGMP facility in Laurelton, NY. The company specializes in oral solid dosage forms (tablets, capsules, powders) and has expanded capabilities into injectables, ophthalmics, and controlled substances. Serving both its own product portfolio and contract manufacturing clients, Epic Pharma benefits from a diversified revenue stream and regulatory compliance with FDA standards. The company's strategic focus on high-demand generic segments and its ability to handle complex formulations position it for steady growth in the competitive US generics market. With a conservative financial profile and no disclosed fundraising, Epic Pharma likely relies on organic cash flows and debt to fund operations, limiting aggressive expansion but ensuring stability. The company's private status reduces transparency, but its approved products and existing manufacturing footprint provide a baseline for predictable earnings.

Upcoming Catalysts (preview)

• Q4 2026FDA Approval of High-Value ANDA70% success
• 2027Expansion into New Dosage Forms (e.g., injectables capacity)80% success
• 2026Major Contract Manufacturing Win with Branded Partner60% success